Trial reportAddiction biology2022
Effects of cannabidiol in cannabis flower: Implications for harm reduction.
Trial report in Addiction biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Investigating the Relationship Between Cannabis Expectancies and Anxiety, Depression, and Pain Responses After Acute Flower and Edible Cannabis Use.Cannabis and cannabinoid research · 2025Trial
- Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-ExperimentalCannabis and cannabinoid research · 2024Trial
- Acute Effects of Ad Libitum Use of Commercially Available Cannabis Products on the Subjective Experience of Aerobic Exercise: A Crossover Study.Sports medicine (Auckland, N.Z.) · 2024Trial
- Simultaneous versus Sequential Cessation of Tobacco and Cannabis: Preferences of Young Adults Who Co-Use in France.Drug and alcohol review · 2026Article
- Cannabidiol dose modulates behavioral response to acute and repeated administration of Δ9-Tetrahydrocannabinol by strain and sex.bioRxiv : the preprint server for biology · 2026Article
- The Cannabis Use Disorder Identification Test - Consumption (CUDIT-C) as a targeted tool for cannabis use screening.Addictive behaviors · 2025Article
- Relationships Between Motives for Cannabis and Cannabidiol Use in People Who Co-Use: Results From the European Web Survey on Drugs.Drug and alcohol review · 2025Article
- Effect of Cannabidiol and Δ9-tetrahydrocannabinol on Anti-Inflammatory Lipid Mediator Synthesis in Humans.Cannabis and cannabinoid research · 2025Article
- Mode matters: exploring how modes of cannabis administration affect THC plasma concentrations and subjective effects.Journal of cannabis research · 2025Article
- The driving-related attitudes, beliefs and behaviours of cannabis users in the Australian Capital Territory following decriminalisation.Drug and alcohol review · 2025Article
- Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.Nutrients · 2025Review
- Perceived Risks and Benefits and Frequency of Cannabis Use Among People with HIV in Different Legal Environments.AIDS research and human retroviruses · 2024Article
- Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.Cannabis and cannabinoid research · 2024Observational
- Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research.Nature. Mental health · 2024Article
- Effects of oral Δ9-tetrahydrocannabinol and cannabidiol combinations on a sustained attention task in rats.Experimental and clinical psychopharmacology · 2023Article
- Research Progress on Cannabinoids inMolecules (Basel, Switzerland) · 2023Review
- Cannabis Involvement and Demand in Frequent Concentrate Users Versus Predominantly Flower Users.Journal of studies on alcohol and drugs · 2023Article
- A daily diary investigation of cannabis use and its diet and exercise correlates.Frontiers in psychology · 2023Article
- A First-Tier Framework for Assessing Toxicological Risk from Vaporized Cannabis Concentrates.Toxics · 2022Article
- Distress tolerance and reactivity to negative affective cues in naturalistic environments of cannabis-using emerging adults.Drug and alcohol dependence · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Using a federally compatible, naturalistic at-home administration procedure, the present study examined the acute effects of three cannabis flower chemovars with different tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios, in order to test whether chemovars with a higher CBD content produce different effects. Participants were randomly assigned to ad libitum administration of one of three chemovars (THC-dominant: 24% THC, 1% CBD; THC+CBD: 9% THC, 10% CBD; CBD-dominant: 1% THC, 23% CBD); 159 regular cannabis users (male = 94, female = 65) were assessed in a mobile pharmacology lab before, immediately after, and 1 h after ad libitum administration of their assigned chemovar. Plasma cannabinoids as well as positive (e.g., high, elation) and negative (e.g., paranoia and anxiety) subjective effects were assessed at each time points. Participants who used the CBD-dominant and THC + CBD chemovars had significantly less THC and more CBD in plasma samples compared to participants who used the THC-dominant chemovar. Further, the THC + CBD chemovar was associated with similar levels of positive subjective effects, but significantly less paranoia and anxiety, as compared to the THC-dominant chemovar. This is one of the first studies to examine the differential effects of various THC to CBD ratios using chemovars that are widely available in state-regulated markets. Individuals using a THC + CBD chemovar had significantly lower plasma THC concentrations and reported less paranoia and anxiety while also reporting similar positive mood effects as compared to individuals using THC only, which is intriguing from a harm reduction perspective. Further research is needed to clarify the harm reduction potential of CBD in cannabis products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.